Equities research analysts expect Bio Blast Pharma Ltd. (NASDAQ:ORPN) to post earnings per share of ($0.22) for the current quarter, according to Zacks. Zero analysts have made estimates for Bio Blast Pharma’s earnings. Bio Blast Pharma also reported earnings per share of ($0.22) in the same quarter last year. The company is expected to issue its next quarterly earnings results on Thursday, August 24th.

On average, analysts expect that Bio Blast Pharma will report full year earnings of ($0.82) per share for the current fiscal year. For the next financial year, analysts anticipate that the business will report earnings of ($0.73) per share. Zacks’ EPS averages are an average based on a survey of research analysts that cover Bio Blast Pharma.

Several equities analysts have weighed in on ORPN shares. S&P Equity Research lifted their price objective on Bio Blast Pharma from $0.56 to $0.63 in a report on Friday, April 28th. ValuEngine cut Bio Blast Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

A hedge fund recently raised its stake in Bio Blast Pharma stock. Renaissance Technologies LLC raised its position in Bio Blast Pharma Ltd. (NASDAQ:ORPN) by 34.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 159,300 shares of the biopharmaceutical company’s stock after buying an additional 40,400 shares during the period. Renaissance Technologies LLC owned about 0.97% of Bio Blast Pharma worth $121,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 3.25% of the company’s stock.

Bio Blast Pharma (ORPN) traded down 2.13% on Thursday, reaching $0.46. The company’s stock had a trading volume of 21,562 shares. The company has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.86. Bio Blast Pharma has a 12 month low of $0.41 and a 12 month high of $2.04. The company’s market cap is $7.54 million.

WARNING: This piece was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/22/brokerages-expect-bio-blast-pharma-ltd-orpn-to-post-0-22-eps.html.

About Bio Blast Pharma

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

Get a free copy of the Zacks research report on Bio Blast Pharma (ORPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.